AlloVir, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 30.3 million compared to USD 41.18 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.44 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.735 USD | 0.00% |
|
-3.20% | +8.12% |
Jun. 11 | AlloVir, Inc. Enter into Termination of Sublease Agreement with AMAG Pharmaceuticals, Inc | CI |
May. 13 | AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.12% | 83.38M | |
+15.58% | 121B | |
+16.60% | 110B | |
+17.73% | 25.93B | |
-24.33% | 19.27B | |
-19.35% | 16.01B | |
-17.95% | 15.66B | |
-48.32% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- ALVR Stock
- News AlloVir, Inc.
- AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024